Introduction
Definitive thoracic radiation therapy with concurrent chemotherapy is the initial treatment for patients who have been diagnosed with unresectable locally advanced but non-metastatic nonsmall cell lung cancer (NSCLC) [1] . Even with radical radiotherapy and use of advanced image-guided and high-precision techniques such as intensity modulated radiotherapy (IMRT) or volumetric arc therapy (VMAT), the rates of locoregional or marginal recurrence, nodal metastasis, and second tumors within the primary irradiated area are very high [2] . Locoregional recurrence of NSCLC is the major cause of death and associated with clinical challenges of diseases control due to limited therapeutic options. Because patients with locoregional relapse or second cancers in the thoracic region after definitive radiotherapy are generally not suitable for surgery and the response rates to second-line chemotherapy are low without the provision of durable control [3] , re-irradiation remains as a treatment option using limited radiation doses which can be tolerated by the surrounding previously irradiated critical tissues. Palliative or definitive re-irradiation of locally recurrent or persistent NSCLC using conventional radiotherapy has been explored by multiple groups reporting variable success with 2-year locoregional control rates of only 42% at a median dose of 51 Gy [4] [5] [6] . In their review, Jeremic et al. [7] summarized that conventional external beam radiotherapy (EBRT) for re-irradiation of recurrent lung cancer yields suboptimal local control rates of 50-60% and a 3-5% risk of grade 3 or higher toxicity. Although retreatment with EBRT should be considered as a useful option if there is potential for symptoms relief without causing unacceptable toxicity, an earlier published series of re-irradiation with stereotactic body radiotherapy (SBRT) techniques with or without chemotherapy showed outcomes comparable to EBRT and encouraging results with local control rates of 65-92% and acceptable treatment-related toxicity [8] [9] [10] .
SBRT is a recently introduced technique that allows delivery of very high radiation doses to the target volume by using multiple planar and non-coplanar beams. CyberKnife ® (Accuray, Sunnyvale, CA, USA) is one of the SBRT delivery systems. The computer-operated robot of the CyberKnife system provides the opportunity to use several beam entrances from different nodes. Because this system allows rapid dose fall-off at the target periphery within a few millimeters, it is a good candidate for re-irradiation of lesions which are close to critical structures such as lungs, esophagus, and heart for which radiation dose tolerances should not be exceeded to avoid serious complications or even death. In patients with recurrent lung disease and symptoms such as hemoptysis, cough, dyspnea, and pain related to tumor growth or previous radiation therapy, the risk of exceeding the radiation dose tolerances of normal tissues adjacent to recurrent or new tumors poses a significant challenge for re-irradiation. Accurate definition of the tumor with improved imaging techniques such as positron emission tomography/computed tomography (PET/CT) or tumor tracking during SBRT with real-time fiducial and breath tracking techniques such as in the CyberKnife system help to provide more accurate dose delivery and safe dose escalation with high conformity while minimizing toxicity. Although there is limited published information on the correlation between dose volume and toxicity for re-irradiation of recurrent NSCLC using SBRT, it appears to be a feasible and safe option for the re-irradiation of lung tumors with the goal of either palliative symptom control, prevention of symptoms due to progressive disease, or cure in the absence of metastatic spread [11, 12] .
In this study, we retrospectively reviewed our institutional experience to evaluate local control rates and acute toxicities by calculating the biologically effective dose (BED) for re-irradiation using SBRT with the CyberKnife robotic radiosurgery device with or without systemic therapy for the treatment of recurrent/persistent or new NSCLC after definitive or palliative radiation therapy.
Patients and Methods

Patients and Initial EBRT
From November 2005 to April 2015, 49 patients who had previous definitive radiation treatment for primary NSCLC and 14 patients who had metastatic disease within the thoracic region underwent SBRT with CyberKnife at our center. 28 patients with 34 in-field or close to the previous field recurrent/ persistent or newly diagnosed lesions were included in this study. The remaining patients were excluded because of a lack of at least 4 months of follow-up time and/or having been diagnosed with distant metastasis around the re-irradiation time by PET/CT or brain magnetic resonance imaging. All 28 patients were evaluable for survival and late toxicities. Patient and tumor specifics are summarized in table 1. All included patients were histologically diagnosed or underwent a chest PET/CT scan at least 4 months after the previous treatment to prove recurrent/persistent disease, and none of the 28 patients had distant metastasis. Only 1 patient had received SBRT as an initial treatment, while the remaining patients had received EBRT such as 3-dimensional conformal radiotherapy (3DCRT), IMRT, or VMAT prior to SBRT re-irradiation for lung recurrence.
Although complete records were not available for all patients, previous treatment information including prescription dose, dose distributions, field or planning target volume (PTV) size, digitally reconstructed radiographs (DRRs) of treatment fields, and dose volume histograms were reviewed. While 14 of the patients had been previously treated at our clinic with either 3DCRT or IMRT/ VMAT, the remaining patients had been treated at a different institution with either 3DCRT or 2-dimensional conventional radiotherapy (2DCRT). All included patients were initially treated with curative intent; 14 patients were treated with an extended field approach using elective nodal irradiation (ENI) to deliver prophylactic radiation to clinically uninvolved lymph nodes, while 13 patients were treated with an involved field radiotherapy (IFRT) approach targeting only gross nodal disease identified by biopsy and/or radiological imaging (according to the available pretreatment information).
A total of 16 patients received concomitant chemotherapy; 3 patients were treated with SBRT during classical first-line chemotherapy and 2 received SBRT during third-line chemotherapy. 2 patients received second-line chemotherapy prior to re-irradiation as a primary treatment after disease recurrence. The most commonly used chemotherapy agents were docetaxel with cisplatin (n = 5), carboplatin with paclitaxel (n = 4), erlotinib alone (n = 2), cisplatin with gemcitabine (n = 2), gemcitabine alone (n = 2), and docetaxel (n = 1) as second-line chemotherapy.
SBRT Planning and Delivery
All patients underwent SBRT in the supine position on a vacuum pad and wearing a respiratory vest with the CyberKnife robotic radiosurgery system. Treatment planning was done using CT scans of the patients applying the breath-hold method, and the gross target volume (GTV) was defined by a radiation oncologist based on combined CT and PET imaging information. The PTVs were created by adding a 5-mm isotropic margin to the GTVs in all cases, even if SBRT was done using spine tumor tracking, which is not a real-time tumor tracking technique unlike Synchrony TM (Accuray) and Xsight TM (Accuray), to take set-up uncertainty into account. If the spinal cord and esophagus had already been irradiated up to the maximum tolerated dose during previous irradiation, they were fully shielded during re-irradiation by reducing the PTV margin.
During the treatment, breathing cycles were tracked using the Synchrony Respiratory System of CyberKnife, and real-time tumor tracking was done using either fiducial (n = 16) or Xsight lung (n = 4) techniques with kV orthogonal imaging. The Xsight spine technique was used in 8 patients. The orthogonal kV image pairs allow for the current tumor position to be defined by fiducial, bone, or internal targets which achieve an isotropic 2-mm smaller (compared to GTV for Xsight lung tracking) volume, and the offset values in 6D direction were obtained by comparing patient DRRs and the current KV image pairs to correct the patient's position throughout treatment. Treatment with CyberKnife currently requires implementation of radio-opaque fiducial markers into the tumor as reference points for tumor tracking. The fiducial markers, which are tiny gold seeds, are usually implanted via a percutaneous or bronchoscopic approach. Patients in whom the fiducial tracking system was used underwent percutaneous fiducial placement of 1-4 gold fiducial markers in and/or close to the target. Treatment planning was performed using non-coplanar pencil beams of 6 MV and a ray-tracing algorithm which uses a path-length correction algorithm for heterogeneity correction. Tissue heterogeneities are accounted for through a central axis effective depth calculation; there are no corrections for changes in electron transport or lateral scatter disequilibrium that may develop in the presence of low-density heterogeneities.
SBRT dose and fractionation were defined considering the interval time between previous EBRT and recurrence, the previous irradiation dose to critical structures such as lungs, spinal cord, esophagus, trachea, and the site of recurrence in terms of in-field or out-of-field. In addition, composite plans could not be generated for all patients due to the used version of the CyberKnife planning system which is not capable of exporting dose distribution; furthermore, most patients had received their previous treatment outside of our hospital. However, the CT images and delineated contours of 14 patients were fused to define overlapping regions. For the remaining patients, CT or DRR images from their previous treatment were used to determine whether the recurrent lesion to be targeted by SBRT is an in-field or out-of-field relapse or a second primary lesion. 20 patients with 21 recurrent tumors had in-field recurrences, and 8 patients with 13 recurrent tumors had regional failure with the possibility of it being inside the low-dose region. The dose prescription ranged from 20 to 60 Gy delivered in 3-9 fractions, depending on the previous treatment dose and technique, size and location of the recurrent lesion, and neighboring critical organs. Only 1 patient was treated with 60 Gy in 3 fractions who had an out-offield recurrence and had received IMRT in our clinic. Doses to critical organs were limited to the lowest amount possible, with the dose to the spinal cord restricted to < 25 Gy for the second radiation course and the ipsilateral lung volume receiving > 20 Gy being kept to a minimum.
The BED was calculated for all patients to investigate the efficiency of the treatment dose in terms of local control and toxicity using the following formula: BED = TDx (1+DFx/(α/β)) TD = Total dose; DFx -dose per fraction; α/β = 10 for tumor response [13] .
Follow-Up
In general, patients were followed up with 3-monthly CT or PET/CT scans comparing target size and changes in standardized uptake value (SUV) to define response to SBRT re-irradiation. All recorded clinical data and clinical examination results were reviewed to evaluate local control, which was defined from the last SBRT date to the date of diagnosis of local progression by chest PET/CT or CT (i.e., size increase and/or increasing SUV). Local failure was defined as recurrence within the PTV. Rates and times of overall survival (OS), progression-free survival (PFS), and distant metastasis were estimated for all treated patients. IBM SPSS Statistics version 20 software (IBM Corp., Armonk, NY, USA) was used for statistical analysis. The Kaplan-Meier method was used to estimate OS, and statistically significant factors for local control and OS such as in-field recurrence, prescription dose value, and tumor volume were analyzed for treatment efficiency using the log-rank test [14] [15] [16] [17] [18] . Assessment of treatment toxicity included dyspnea, and symptoms were investigated through personal communication with the patients and their families. Both acute and late toxicities were retrospectively scored according to the toxicity criteria of the Common Terminology Criteria for Adverse Effect version 4.0 (CTCAE v4).
Results
Patients
A total of 28 inoperable patients with 34 recurrent or persistent re-irradiated tumors, of which 3 lesions received a second course of SBRT re-irradiation after re-diagnosed local failure, were retrospectively analyzed. The median age was 64 years (range 48-90 years). 3 of the 28 patients were women and 25 were men. All patients had histologically proven NSCLC at the time of EBRT, and intrathoracic tumor recurrence after EBRT was defined as progression in terms of tumor size or persistent lesions on CT images and/ or increased SUV on PET scan. Each case was discussed by our tumor board to determine eligibility for re-irradiation with robotic SBRT, taking into account the patient's overall performance and suitability for fiducial placement and SBRT. 22 patients had received definitive EBRT with a median delivered dose of 59.4 Gy (range 47.5-66 Gy), 5 patients had received postoperative adjuvant EBRT with a median delivered dose of 56 Gy (range 50.4-60 Gy), and 1 patient had been treated with SBRT at 60 Gy. The initial EBRT was delivered using 2DCRT (n = 2), 3DCRT (n = 12), IMRT (n = 12), VMAT (n = 1), and robotic radiosurgery (n = 1). The median follow-up duration after SBRT was 9 months (range 3-93 months). 6 of the patients had been lost to follow-up by the time of the second CT or PET/CT scan, and 1 of the patients had died by the time of the second check-up. Because of 2 recurrent or new lesions at the time of the SBRT decision, 4 of the 28 patients underwent SBRT separately, and 2 patients received SBRT as a third thoracic radiotherapy and a second re-irradiation course. 1 patient underwent a second course of SBRT for newly diagnosed lymph node lesions inside the previous treatment site with 30 Gy in 6 fractions. 4 patients are still alive and under follow-up at our clinic. 16 of the 28 patients had died by the time of this analysis, while the status of 8 of the remaining patients was unknown due to a lack of information.
SBRT
The median interval time from previous EBRT to robotic SBRT re-irradiation was 14 months (range 4-56 months). A total of 21 lesions were defined as in-field recurrences or ambiguous lesion located inside the GTV, clinical target volume (CTV), or PTV according to CT or PET/CT. Details of SBRT are shown in table 2. 13 of a total of 34 tumors were accepted as out-of-field recurrences or new primaries located outside the CTV and GTV but possibly inside the PTV or low-dose region. None of the patients had stable or newly diagnosed distant metastatic disease at the time of re-irradiation. 16 of the included patients received systemic chemotherapy at the time of SBRT and following SBRT. The tumor volumes ranged from 2.3 cm 3 to 156.3 cm 3 (median 24.2 cm 3 ). There were 18 peripheral tumors and 16 central tumors.
The median prescription radiation dose was 30 Gy in 5 fractions; the BED (with α/β = 10 Gy) was 48 Gy, while the median BED 10 was 56.25 Gy. The BED ranged between 28 and 112.5 Gy. 10 of all tumors were treated with BED 10 = 112.5 Gy, 2 were treated with BED 10 = 85.5 Gy, 2 with BED 10 = 20 Gy, 1 with BED 10 = 72 Gy, 1 with BED 10 = 67.5 Gy, 2 with BED 10 = 60 Gy, 1 with BED 10 = 52.5 Gy, 10 with BED 10 = 48 Gy, 3 with BED 10 = 45 Gy, 1 with BED 10 = 42.5 Gy, 2 with BED 10 = 28 Gy, 1 with BED 10 = 41.25 Gy, and 1 with BED 10 = 180 Gy. The dose was prescribed to an isodose line (median 80%, range 73-90%) covering 95% of the PTV. Suboptimal or compromised PTV coverage was achieved in most of the patients. Figure 1 shows images of the planning and follow-up CT and PET/CT of a patient who underwent WMAT as the initial treatment with 6,572 cGy to the GTV, 5,425 cGy to the PTV, and SBRT with 30 Gy in 5 fractions because of in-field relapse. The SBRT dose decision was made based on whether the BED was < 48 Gy or 48 Gy and taking into account the following criteria: interval time, site of recurrence, and distance to critical structures. The majority of patients were treated with BED 48 Gy even for recurrent lesions inside the previous treatment field based on adherence to the required interval time between treatments and the dose to critical structures being acceptable.
Survival, Local Control, and Follow-Up
Local control after re-irradiation was evaluated as complete response (CR) or partial response (PR) in patients evaluable for radiographic response. The median interval time from prior EBRT was 15 months (range 4-56). Median follow-up was 9 months (range 3-93 months). At the time of this analysis, 16 of the 28 patients had died, and 8 of the 28 patients had been lost to follow-up. Figure 2 demonstrates the first PET/CT image showing local infield recurrence after first treatment of a patient who achieved CR and an OS of 93 months, as well as planning details and follow-up images up to the last PET/CT. 
At the first 3-monthly follow-up after SBRT, CR was observed in 13 patients, PR in 13 patients, stable disease in 1 patient, and local progression in 1 patient (accepted as presenting with local failure as assessed by chest CT and/or PET/CT). The patient with local failure was treated with 30 Gy in 5 fractions. At the time of the first follow-up, locoregional lymph node lesions or newly diagnosed recurrent lesions inside the previous treatment region but different from the re-irradiated GTV occurred in 4 patients who had achieved at least a PR of the local disease. Only 1 of 4 patients underwent a second CyberKnife SBRT with 20 Gy in 5 fractions. Distant failure had occurred in 2 patients at the time of the first follow-up according to PET/CT imaging while presenting with local CR. Local control was defined for each lesion as local PFS, and the 5-year actuarial survival by yearly periods was calculated. The Kaplan-Meier plot of local control for all treated tumors is depicted in figure 3 . At the time of the second follow-up imaging study, local progression was observed in 1 patient who had been treated with BED 48 Gy, while 6 patients with BED < 48 Gy had local failure. The actuarial local progression-free control rates were 69% at 1 year and 37% at 2 years. The interval time between EBRT and re-irradiation SBRT did not affect PFS and OS in the statistical analysis.
The effect of low-dose BED < 48 Gy and high-dose BED 48 Gy on local control was found to be significant (p = 0.007). Median local control was 13 months for BED < 48 Gy and 48 months for BED 48 Gy. The effect of concurrent chemotherapy, including recurrence and tumor volume, on local control was not significant. The Kaplan-Meier plot of the effect of dose on local control is given in figure 4 . The estimated 1-and 2-year actuarial OS rates were 71 and 42%, respectively. The mean survival of the patients following CyberKnife therapy was 32.8 months; and median survival was 21 months. Kaplan-Meier estimates of overall PFS (median 19 months) are shown in the figure 5. The overall toxicity was acceptably low in that no acute and late toxicity greater than grade 2 was observed; only 1 patient had grade 2 radiation pneumonitis after SBRT. 1 patient died within less than 6 months of follow-up, who had grade 2 radiation pneumonitis as a toxicity of SBRT with an underlying thoracic embolism attributed to either disease progression or acute radiation pneumonitis. 7 patients who had no local progression at the time of the first follow-up experienced grade 1-2 coughs or dyspnea not requiring supplemental oxygen. Patients who underwent a second Cyberknife SBRT because of local failure or new or recurrent lesions, also tolerated this without any more than grade 2-3 toxicity. We found no differences in the effect of the previously used treatment techniques on local control or toxicities. No correlation was found between toxicity and BED values. While most of the severe toxicities were noted within the first year of follow-up, some late toxic effects could not have been identified (except dyspnea below grade 2 in 3 patients who had longer follow-up) because of the short median follow-up time (9 months) and late clinical admission to our hospital when toxicities occurred.
Discussion
Locoregional recurrence or disease progression is common after EBRT for NSCLC. In this article, we present our experience with re-irradiation using robotic radiosurgery in recurrent NSCLC patients who had been previously treated with EBRT. Indications for repeat irradiation can be divided into 4 categories: emergent symptomatic; symptomatic but not emergent such as dyspnea; asymptomatic but impending serious event such as airway obstruction; or radiological tumor progression without symptoms. Drodge et al. [19] reviewed that specific indications for irradiation were applied on a case-by-case basis at the discretion of the radiation oncologist. In our retrospective study, stringent eligibility criteria for irradiation were applied: minimal interval time between first EBRT and diagnosis of recurrence of 4 months, and confirmation of the patient's performance status by the pulmonologist. However, similarly to published data by Gressen et al. [20] , our results show that the interval time from the completion of the initial EBRT to recurrence did not significantly influence OS. Potential radiation injury, limited re-irradiation prescription doses because of a lack of previous EBRT details, normal tissue tolerance levels, and the lack of guidelines and relevant experiences can make decisions difficult in the setting of re-irradiation with SBRT. With respect to treatment planning, highly conformal EBRT such as IMRT can provide maximal normal tissue sparing and is preferable for SBRT re-irradiation with radical intent. Because we were unable to construct cumulative dose plans, the critical organ doses in the SBRT plans could not be quantitatively clarified in this study.
Although recently published reports [21] [22] [23] agree that doses of > 100 Gy BED to the tumor are necessary for local control and improved survival in patients with early-stage NSCLC who cannot be operated on because of medical comorbidities or who refuse surgical resection, there is still controversy about SBRT for centrally located NSCLC and irradiation of recurrent NSCLC due to a lack of agreement regarding the radiation dose. Schanne et al. [24] reviewed SBRT experiences of 20 single centers with centrally located NSCLC and concluded that SBRT for centrally located early-stage NSCLC was safe with no local failure reported in the patients treated with a BED 10 100 Gy during the follow-up period. Even if the BED 10 100 Gy SBRT dose for centrally located tumors is sufficiently high to achieve better local control, central tumors were generally treated with more fractions and lower fraction doses compared to peripheral lesions, resulting in a relatively low toxicity rate. While therapeutic uncertainties still exist in clinical practice with regard to central NSCLC, it will be helpful to establish a dosetoxicity relationship for the irradiation of recurrent pulmonary lesions. Re-irradiation of recurrent thoracic lesions remains a challenging part of SBRT with radiation doses limited by the tolerance levels of the surrounding critical tissues after previous radiation treatment. Wu et al. [25] in their phase I/II prospective study of thoracic re-irradiation using conventional techniques revealed a median OS of 14 months and a PFS rate of 42% for 2 years with no more than grade 3 toxicity. Kilburn et al. [26] presented their results with 33 patients previously treated with either EBRT or SBRT who were re-irradiated using only the SBRT approach. The local control rate (2 years) was at 67% relatively smaller than that of the MDACC series with 92%, because of heterogonous tumor location and a higher BED value (50 Gy in 4 fraction vs. 50 Gy in 10 fractions) [26] . Comparing these published data and our results (heterogeneous populations in terms of recurrence sites), we found similar local control, PFS, and toxicity. Our results show a statistically significant effect of BED < 48 Gy and BED 48 Gy on local control as opposed to published data by Patel et al. [13] , but potential toxicity and retreatment dose still pose a dilemma for radiation oncologists when deciding on re-irradiation of in-field recurrences. Kelly et al. [27] published their series of higher-dose re-irradiation with high control rates and a 2-year actuarial PFS rate similar to our results (progression-free local control 69% at 1 year and 37% at 2 years). In this study, the OS rate after re-irradiation with radical intent was 71% at 1 year and 42% at 2 years, with a median survival time of 21 months, which was in agreement with another published series in which relatively higher re-irradiation SBRT doses were used [28] . Despite improved local control and OS with higher-dose re-irradiation SBRT, re-irradiation of recurrent lung cancer should be considered carefully in terms of potentially increased toxicity and high rates of distant failure. Although the effect of concurrent systematic treatment on local control was not significant in our series, it is conceivable that concurrent systematic therapy could decrease distant metastatic failure.
Ideally, we tried to achieve an optimal plan in which at least 95% of the PTV of the SBRT plans would be covered by a prescription isodose line and none of the PTV would receive more than 107% of the prescription dose. However, due to a lack of information including critical organ doses of previous EBRT and no specific dose recommendations in the literature for re-irradiation of lung tumors, covering the PTV with the prescription isodose line was limited by the need to spare critical tissues such as lung, esophagus, and vascular structures as much as possible. One limitation of our study was that composite plans were not constructed because of limitation of the planning system and a lack of access to previous treatment plans of the patients. Most authors mathematically added up previous EBRT and SBRT doses by calculating the equivalent dose in 2 Gy (EQD2) per fraction to decide the dosimetric parameters of their SBRT plans [28, 29] . Meijneke et al. [30] reported that re-irradiation of recurrent lung tumors with a median accumulated D max of 363 Gy 3 appeared to be feasible and safe with acceptable toxicity in selected patient. Our results show that good local control rates could be achieved with BED 48 with low toxicity in selected patients.
Re-irradiation after EBRT with SBRT for patients with locoregional recurrences or newly diagnosed tumors within the previously treated region offers an option for selected inoperable patients with probably better control rates than systemic treatment and 3DCRT [31] . Tada et al. [5] reported that the OS rates for 19 patients who were re-irradiated with conformal radiotherapy were 26 and 11% for years 1 and 2, respectively. A comparison of our SBRT result with published data by Wu et al. [4] who used 3DCRT shows that a better local control rate can be obtained with SBRT with a 1-year rate of 69% compared to 51%.
In this study, the rate and grade of toxicity related to re-irradiation with SBRT were acceptable and tolerable with 17 patients having experienced no toxicity by the time of the first and second follow-up and toxicities in the remaining patients including fatigue, radiation pneumonitis, and cough all below grade 3. Dosimetric parameters and patient factors were not statistically meaningful in predicting acute toxicity. Due to the limited number of cases in our study, the median follow-up was relatively short, the included tumor locations were inhomogeneous (in-and outside the previous field), and the median prescription dose was relatively low (BED = 56.25 Gy) compared with other studies [27, 32] , which may have caused an underestimation of the toxicity of re-irradiation. Other studies [27, 32] also concluded that re-irradiation with SBRT is feasible but to be aware of an increased risk of toxicity when treating centrally located lung tumors. Even though the number of included patients was rather small and follow-up was too short to draw clinical conclusions, our reported toxicity and local control rates for re-irradiation with robotic radiosurgery of locally recurrent NSCLC are comparable and consistent with other published data [12, 30, 33] .
While no comparison is available for different SBRT techniques such as IMRT, VMAT, or CyberKnife, Coon et al. [34] published their data for recurrent lung cancer patients retreated with the CyberKnife radiosurgery system. The Synchrony system offers realtime breathing and tumor tracking with implemented fiducial markers and permits patients to breathe normally compared to breath-hold or abdominal compression. Thus, critical organ protection can be done better than with other techniques, and this option allows for margin reduction to the GTV for movement uncertainty.
Although the decision whether or not to re-irradiate patients with locally relapsed cancer is difficult to make, our findings demonstrate that robotic radiosurgery re-irradiation is a promising option for NSCLC patients who have previously received high-dose EBRT, which should be reviewed on a case-by-case basis by a multidisciplinary tumor board. SBRT doses in patients being treated for recurrent lung tumors should be carefully chosen with attention to cumulative doses to close-by critical organs, interval time between EBRT and SBRT, present comorbidities of the patient, and prognosis. Our future plan is to design prospective studies to determine optimal treatment doses and fractionation schemes with acceptable toxicity for selective patients to achieve better local control.
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